Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
19 hedge funds and large institutions have $9.12M invested in Yield10 Bioscience, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
10% less funds holding
Funds holding: 21 → 19 (-2)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
42% less capital invested
Capital invested by funds: $15.6M → $9.12M (-$6.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$351K |
| 2 |
CC
Cannell & Co
New York
|
+$278K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$220K |
| 4 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
+$57.4K |
| 5 |
Two Sigma Advisers
New York
|
+$53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.1M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$474K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$352K |
| 4 |
BC
Birchview Capital
Burlington,
Vermont
|
-$238K |
| 5 |
Renaissance Technologies
New York
|
-$126K |
YTEN Hedge Fund Activity: Q2 2021 in Review
19 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q2 2021, worth a combined $9.12M — down 42% from $15.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of YTEN and 3 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $351K. The largest seller was Morgan Stanley, cutting an estimated $1.1M.
- 19 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q2 2021, down from 21 in Q1 2021.
- Funds reported $9.12M of Yield10 Bioscience, Inc. Common Stock stock for Q2 2021, down 42% quarter-over-quarter.
- 3 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q2 2021 and 4 closed out, a net change of -1 holder.
- The largest Yield10 Bioscience, Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $351K added.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q2 2021 was Morgan Stanley, an estimated $1.1M sold.
Based on aggregated 13F filings for Q2 2021.